Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 20(2): 479-82, 2010 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-20005704

RESUMO

A novel class of cannabinoid-1 (CB1) receptor antagonists for the treatment of obesity is presented. The carboxamide linker in a set of 5,6-diaryl-pyrazine-2-amide derivatives was transformed into the corresponding thioamide, by using a one-pot synthesis. The structural series of thioamides not only showed retained CB1 potency (below 10nM), but also showed improved solubility. In addition, the neutral antagonist 2c significantly reduced body weight in cafeteria diet obese mice.


Assuntos
Fármacos Antiobesidade/química , Pirazinas/química , Receptor CB1 de Canabinoide/antagonistas & inibidores , Tioamidas/química , Animais , Fármacos Antiobesidade/síntese química , Fármacos Antiobesidade/farmacocinética , Modelos Animais de Doenças , Camundongos , Camundongos Obesos , Obesidade/tratamento farmacológico , Pirazinas/farmacocinética , Receptor CB1 de Canabinoide/metabolismo , Relação Estrutura-Atividade , Tioamidas/síntese química , Tioamidas/farmacocinética
2.
J Med Chem ; 60(23): 9545-9564, 2017 12 14.
Artigo em Inglês | MEDLINE | ID: mdl-29111736

RESUMO

We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB1 receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [35S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB1 receptor and their structure-kinetic relationships (SKRs) were established. Using the recently resolved hCB1 receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in the early phases of drug discovery.


Assuntos
Imidazóis/química , Imidazóis/farmacologia , Receptor CB1 de Canabinoide/antagonistas & inibidores , Animais , Células CHO , Cricetulus , Descoberta de Drogas , Células HEK293 , Humanos , Cinética , Modelos Moleculares , Simulação de Acoplamento Molecular , Receptor CB1 de Canabinoide/metabolismo , Relação Estrutura-Atividade
3.
ACS Med Chem Lett ; 5(5): 538-43, 2014 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-24900876

RESUMO

A class of novel oral fibrinolysis inhibitors has been discovered, which are lysine mimetics containing an isoxazolone as a carboxylic acid isostere. As evidenced by X-ray crystallography the inhibitors bind to the lysine binding site in plasmin thus preventing plasmin from binding to fibrin, hence blocking the protein-protein interaction. Optimization of the series, focusing on potency in human buffer and plasma clotlysis assays, permeability, and GABAa selectivity, led to the discovery of AZD6564 (19) displaying an in vitro human plasma clot lysis IC50 of 0.44 µM, no detectable activity against GABAa, and with DMPK properties leading to a predicted dose of 340 mg twice a day oral dosing in humans.

4.
Fundam Clin Pharmacol ; 25(2): 200-10, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20608998

RESUMO

The implication of the cannabinoid receptor 1 (CB(1) receptor) in several pathophysiological states has sparked the development of selective antagonists. Here we compare binding of the antagonists [(3) H]-AZ12491187, [(3) H]-taranabant and [(3) H]-rimonabant to intact human embryonic kidney cells stably expressing recombinant human CB(1) receptors (CB1r cells). Unlabelled ligands decreased the total binding of the three radioligands with closely the same order of potency: i.e. AZ12288553∼AZ12491187∼taranabant>rimonabant. Nondisplaceable (i.e. nonspecific) binding to the CB1r cells was the same as total binding to the wells containing untransfected cells and it was more pronounced for [(3) H]-AZ12491187 and [(3) H]-rimonabant than for [(3) H]-taranabant. [(3) H]-Rimonabant and (to a lesser extent) [(3) H]-AZ12491187 were also prone to bind nonspecifically to the walls of the wells. Compared to the other radioligands, [(3) H]-rimonabant displayed lower potency for the CB(1) receptors in saturation binding studies and faster association and dissociation in kinetic experiments. When dissociated, the three radioligands also showed prominent rebinding to the cells in medium only. This could be relieved by the presence of excess of unlabelled ligand and of bovine serum albumin (BSA) but a combination thereof was most efficient. The long 'residence time' of AZ12491187 at the CB(1) receptor (because of slow dissociation and prominent rebinding) and its pronounced incorporation into the membranes of the cells could contribute to long-lasting in vivo CB(1) receptor blockade.


Assuntos
Amidas/metabolismo , Piperidinas/metabolismo , Pirazóis/metabolismo , Piridinas/metabolismo , Receptor CB1 de Canabinoide/antagonistas & inibidores , Sulfonas/metabolismo , Células HEK293 , Humanos , Ligantes , Ligação Proteica , Receptor CB1 de Canabinoide/metabolismo , Rimonabanto , Soroalbumina Bovina/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA